25 XP   0   0   10

Mega Lifesciences Public Company Limited
Buy, Hold or Sell?

Let's analyse Mega Lifesciences Public Company Limited together

PenkeI guess you are interested in Mega Lifesciences Public Company Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Mega Lifesciences Public Company Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Mega Lifesciences Public Company Limited

I send you an email if I find something interesting about Mega Lifesciences Public Company Limited.

Quick analysis of Mega Lifesciences Public Company Limited (30 sec.)










What can you expect buying and holding a share of Mega Lifesciences Public Company Limited? (30 sec.)

How much money do you get?

How much money do you get?
฿0.05
When do you have the money?
1 year
How often do you get paid?
97.5%

What is your share worth?

Current worth
฿10.28
Expected worth in 1 year
฿10.78
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
฿2.15
Return On Investment
5.3%

For what price can you sell your share?

Current Price per Share
฿40.50
Expected price per share
฿39.39 - ฿43.25
How sure are you?
50%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1. Valuation of Mega Lifesciences Public Company Limited (5 min.)




Live pricePrice per Share (EOD)

฿40.50

Intrinsic Value Per Share

฿12.32 - ฿33.14

Total Value Per Share

฿22.60 - ฿43.43

2. Growth of Mega Lifesciences Public Company Limited (5 min.)




Is Mega Lifesciences Public Company Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$258.2m$242.4m$17m6.6%

How much money is Mega Lifesciences Public Company Limited making?

Current yearPrevious yearGrowGrow %
Making money$13.8m$16.8m-$3m-21.8%
Net Profit Margin12.5%15.5%--

How much money comes from the company's main activities?

3. Financial Health of Mega Lifesciences Public Company Limited (5 min.)




3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

What can you expect buying and holding a share of Mega Lifesciences Public Company Limited? (5 min.)

Welcome investor! Mega Lifesciences Public Company Limited's management wants to use your money to grow the business. In return you get a share of Mega Lifesciences Public Company Limited.

What can you expect buying and holding a share of Mega Lifesciences Public Company Limited?

First you should know what it really means to hold a share of Mega Lifesciences Public Company Limited. And how you can make/lose money.

Speculation

The Price per Share of Mega Lifesciences Public Company Limited is ฿40.50. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Mega Lifesciences Public Company Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Mega Lifesciences Public Company Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ฿10.28. Based on the TTM, the Book Value Change Per Share is ฿0.12 per quarter. Based on the YOY, the Book Value Change Per Share is ฿0.30 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ฿0.41 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Mega Lifesciences Public Company Limited.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ฿% of Price per Share฿% of Price per Share฿% of Price per Share฿% of Price per Share฿% of Price per Share
Usd Eps0.020.0%0.020.0%0.020.0%0.010.0%0.010.0%
Usd Book Value Change Per Share0.000.0%0.000.0%0.010.0%0.010.0%0.010.0%
Usd Dividend Per Share0.020.1%0.010.0%0.010.0%0.010.0%0.010.0%
Usd Total Gains Per Share0.020.0%0.020.0%0.020.0%0.020.0%0.010.0%
Usd Price Per Share1.28-1.23-1.39-1.11-0.92-
Price to Earnings Ratio18.11-19.77-18.24-20.40-25.10-
Price-to-Total Gains Ratio68.39-92.53-69.60-83.20-97.94-
Price to Book Ratio4.33-4.13-5.00-4.54-4.67-
Price-to-Total Gains Ratio68.39-92.53-69.60-83.20-97.94-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.1664
Number of shares857
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.01
Usd Book Value Change Per Share0.000.01
Usd Total Gains Per Share0.020.02
Gains per Quarter (857 shares)13.2712.90
Gains per Year (857 shares)53.0751.62
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1411243312142
2812596614294
3122371499263146
41634920212384198
520462255153105250
624474308184126302
728586361215147354
832699414245168406
9367111467276189458
10407123520306210510

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%44.00.00.0100.0%
Book Value Change Per Share2.02.00.050.0%9.03.00.075.0%15.05.00.075.0%27.013.00.067.5%30.014.00.068.2%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%39.00.01.097.5%42.00.02.095.5%
Total Gains per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%44.00.00.0100.0%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

Fundamentals of Mega Lifesciences Public Company Limited

About Mega Lifesciences Public Company Limited

Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter (OTC) products, herbal products, vitamins, and fast moving consumer goods. The company operates through three segments: Brands, Distribution, and Original Equipment Manufacture. It provides various medicines for allergy, blood circulation and memory, bone and joint, kids, liver and digestive, eye, heart, pain, skin, sleeping, well-being, herbal, and cough and cold care, as well as vitamins, probiotics, medical and sports nutrition, and men's and women's care products; and prescription medicines in the areas of anti-allergic, anti-infective, central nervous system, cardio vascular system, dermatology, diabetes, gastroenterology, gynaecology, nephrology, oncology, ophthalmology, orthopaedic, pain, respiratory, rheumatology, and urology. The company also offers logistical and marketing services for the sale of goods manufactured by third parties, as well as involved in the software design, development, and other services business. It operates in the Asia Pacific, the Middle East, Africa, and the Commonwealth of Independent States. The company was incorporated in 1982 and is headquartered in Bangkok, Thailand. Mega Lifesciences Public Company Limited is a subsidiary of Unistretch Limited.

Fundamental data was last updated by Penke on 2023-11-22 13:20:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is underpriced.
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.1. Profitability of Mega Lifesciences Public Company Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Mega Lifesciences Public Company Limited earns for each ฿1 of revenue.

  • Above 10% is considered healthy but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 14.1% means that ฿0.14 for each ฿1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 14.1%. The company is making a huge profit. +2
  • The TTM is 12.5%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ14.1%TTM12.5%+1.6%
TTM12.5%YOY15.5%-3.0%
TTM12.5%5Y12.5%-0.1%
5Y12.5%10Y10.8%+1.7%
1.1.2. Return on Assets

Shows how efficient Mega Lifesciences Public Company Limited is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • 3.6% Return on Assets means that Mega Lifesciences Public Company Limited generated ฿0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 3.6%. Using its assets, the company is less efficient in making profit.
  • The TTM is 3.3%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ3.6%TTM3.3%+0.4%
TTM3.3%YOY4.2%-0.9%
TTM3.3%5Y3.5%-0.2%
5Y3.5%10Y3.1%+0.4%
1.1.3. Return on Equity

Shows how efficient Mega Lifesciences Public Company Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • 6.0% Return on Equity means Mega Lifesciences Public Company Limited generated ฿0.06 for each ฿1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 6.0%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 5.3%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ6.0%TTM5.3%+0.7%
TTM5.3%YOY6.9%-1.6%
TTM5.3%5Y5.8%-0.5%
5Y5.8%10Y5.2%+0.6%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.2. Operating Efficiency of Mega Lifesciences Public Company Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Mega Lifesciences Public Company Limited is operating .

  • Measures how much profit Mega Lifesciences Public Company Limited makes for each ฿1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ฿0.00  for each ฿1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM3.1%-3.1%
TTM3.1%YOY17.4%-14.4%
TTM3.1%5Y12.7%-9.7%
5Y12.7%10Y9.1%+3.6%
1.2.2. Operating Ratio

Measures how efficient Mega Lifesciences Public Company Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.35 means that the operating costs are ฿1.35 for each ฿1 in net sales.

Let's take a look of the Operating Ratio trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 1.354. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.372. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.354TTM1.372-0.018
TTM1.372YOY1.387-0.015
TTM1.3725Y1.423-0.052
5Y1.42310Y1.163+0.261
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.3. Liquidity of Mega Lifesciences Public Company Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Mega Lifesciences Public Company Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.95 means the company has ฿1.95 in assets for each ฿1 in short-term debts.

Let's take a look of the Current Ratio trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 1.946. The company is able to pay all its short-term debts. +1
  • The TTM is 1.982. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.946TTM1.982-0.036
TTM1.982YOY1.941+0.041
TTM1.9825Y1.836+0.146
5Y1.83610Y1.302+0.533
1.3.2. Quick Ratio

Measures if Mega Lifesciences Public Company Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.71 means the company can pay off ฿0.71 for each ฿1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 0.709. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.670. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.709TTM0.670+0.039
TTM0.670YOY0.736-0.066
TTM0.6705Y0.699-0.029
5Y0.69910Y0.781-0.082
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.4. Solvency of Mega Lifesciences Public Company Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Mega Lifesciences Public Company Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Mega Lifesciences Public Company Limited to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.39 means that Mega Lifesciences Public Company Limited assets are financed with 39.2% credit (debt) and the remaining percentage (100% - 39.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 0.392. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.387. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.392TTM0.387+0.005
TTM0.387YOY0.393-0.006
TTM0.3875Y0.401-0.014
5Y0.40110Y0.405-0.004
1.4.2. Debt to Equity Ratio

Measures if Mega Lifesciences Public Company Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 64.4% means that company has ฿0.64 debt for each ฿1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 0.644. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.632. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.644TTM0.632+0.012
TTM0.632YOY0.648-0.017
TTM0.6325Y0.673-0.041
5Y0.67310Y0.684-0.011
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

2. Market Valuation of Mega Lifesciences Public Company Limited

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ฿1 in earnings Mega Lifesciences Public Company Limited generates.

  • Above 15 is considered overpriced but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 18.11 means the investor is paying ฿18.11 for every ฿1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Mega Lifesciences Public Company Limited:

  • The EOD is 16.483. Based on the earnings, the company is fair priced.
  • The MRQ is 18.111. Based on the earnings, the company is fair priced.
  • The TTM is 19.771. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD16.483MRQ18.111-1.628
MRQ18.111TTM19.771-1.660
TTM19.771YOY18.243+1.529
TTM19.7715Y20.396-0.625
5Y20.39610Y25.097-4.701
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Mega Lifesciences Public Company Limited:

  • The EOD is 14.512. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 15.946. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 20.606. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD14.512MRQ15.946-1.433
MRQ15.946TTM20.606-4.661
TTM20.606YOY61.415-40.808
TTM20.6065Y72.568-51.961
5Y72.56810Y48.780+23.788
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Mega Lifesciences Public Company Limited is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 4.33 means the investor is paying ฿4.33 for each ฿1 in book value.

Let's take a look of the Price to Book Ratio trends of Mega Lifesciences Public Company Limited:

  • The EOD is 3.939. Based on the equity, the company is fair priced.
  • The MRQ is 4.328. Based on the equity, the company is fair priced.
  • The TTM is 4.130. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.939MRQ4.328-0.389
MRQ4.328TTM4.130+0.197
TTM4.130YOY5.000-0.869
TTM4.1305Y4.538-0.408
5Y4.53810Y4.673-0.135
2. Total Gains per Share
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Mega Lifesciences Public Company Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.1490.125-219%0.297-150%0.212-170%0.204-173%
Book Value Per Share--10.28310.3340%9.655+7%8.476+21%6.799+51%
Current Ratio--1.9461.982-2%1.941+0%1.836+6%1.302+49%
Debt To Asset Ratio--0.3920.387+1%0.3930%0.401-2%0.405-3%
Debt To Equity Ratio--0.6440.632+2%0.648-1%0.673-4%0.684-6%
Dividend Per Share--0.8000.413+94%0.403+98%0.310+158%0.304+163%
Eps--0.6140.550+12%0.670-8%0.496+24%0.366+68%
Free Cash Flow Per Share--0.6980.659+6%0.381+83%0.469+49%0.384+81%
Free Cash Flow To Equity Per Share---0.3580.160-323%-0.027-92%0.122-393%0.214-267%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--33.144--------
Intrinsic Value_10Y_min--12.321--------
Intrinsic Value_1Y_max--2.422--------
Intrinsic Value_1Y_min--1.496--------
Intrinsic Value_3Y_max--7.963--------
Intrinsic Value_3Y_min--4.295--------
Intrinsic Value_5Y_max--14.329--------
Intrinsic Value_5Y_min--6.854--------
Market Cap35310735648.000-10%38798215712.00037163459432.000+4%42013236396.000-8%33532120815.360+16%27737018658.255+40%
Net Profit Margin--0.1410.125+13%0.155-9%0.125+12%0.108+30%
Operating Margin---0.031-100%0.174-100%0.127-100%0.091-100%
Operating Ratio--1.3541.372-1%1.387-2%1.423-5%1.163+16%
Pb Ratio3.939-10%4.3284.130+5%5.000-13%4.538-5%4.673-7%
Pe Ratio16.483-10%18.11119.771-8%18.243-1%20.396-11%25.097-28%
Price Per Share40.500-10%44.50042.625+4%48.188-8%38.460+16%31.805+40%
Price To Free Cash Flow Ratio14.512-10%15.94620.606-23%61.415-74%72.568-78%48.780-67%
Price To Total Gains Ratio62.247-10%68.39592.530-26%69.603-2%83.202-18%97.936-30%
Quick Ratio--0.7090.670+6%0.736-4%0.699+1%0.781-9%
Return On Assets--0.0360.033+11%0.042-14%0.035+5%0.031+18%
Return On Equity--0.0600.053+12%0.069-14%0.058+3%0.052+16%
Total Gains Per Share--0.6510.538+21%0.700-7%0.523+24%0.508+28%
Usd Book Value--258205276.800259486711.2000%242431056.000+7%212830349.760+21%170762878.152+51%
Usd Book Value Change Per Share---0.0040.004-219%0.009-150%0.006-170%0.006-173%
Usd Book Value Per Share--0.2960.2980%0.278+7%0.244+21%0.196+51%
Usd Dividend Per Share--0.0230.012+94%0.012+98%0.009+158%0.009+163%
Usd Eps--0.0180.016+12%0.019-8%0.014+24%0.011+68%
Usd Free Cash Flow--17518867.20016540905.600+6%9555559.200+83%11776946.400+49%9654656.544+81%
Usd Free Cash Flow Per Share--0.0200.019+6%0.011+83%0.014+49%0.011+81%
Usd Free Cash Flow To Equity Per Share---0.0100.005-323%-0.001-92%0.004-393%0.006-267%
Usd Market Cap1016949186.662-10%1117388612.5061070307631.642+4%1209981208.205-8%965725079.482+16%798826137.358+40%
Usd Price Per Share1.166-10%1.2821.228+4%1.388-8%1.108+16%0.916+40%
Usd Profit--15423782.40013818556.800+12%16834687.200-8%12450607.200+24%9196952.760+68%
Usd Revenue--109524643.200110936678.400-1%108531907.200+1%97829386.560+12%80382626.064+36%
Usd Total Gains Per Share--0.0190.015+21%0.020-7%0.015+24%0.015+28%
 EOD+4 -4MRQTTM+20 -15YOY+17 -185Y+28 -710Y+26 -9

3.2. Fundamental Score

Let's check the fundamental score of Mega Lifesciences Public Company Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1516.483
Price to Book Ratio (EOD)Between0-13.939
Net Profit Margin (MRQ)Greater than00.141
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.709
Current Ratio (MRQ)Greater than11.946
Debt to Asset Ratio (MRQ)Less than10.392
Debt to Equity Ratio (MRQ)Less than10.644
Return on Equity (MRQ)Greater than0.150.060
Return on Assets (MRQ)Greater than0.050.036
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Mega Lifesciences Public Company Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.634
Ma 20Greater thanMa 5041.038
Ma 50Greater thanMa 10043.005
Ma 100Greater thanMa 20041.788
OpenGreater thanClose40.250
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in THB. All numbers in thousands.

Summary
Total Assets14,738,993
Total Liabilities5,773,532
Total Stockholder Equity8,965,475
 As reported
Total Liabilities 5,773,532
Total Stockholder Equity+ 8,965,475
Total Assets = 14,738,993

Assets

Total Assets14,738,993
Total Current Assets10,555,119
Long-term Assets10,555,119
Total Current Assets
Cash And Cash Equivalents 2,114,248
Short-term Investments 336,957
Net Receivables 3,508,783
Inventory 3,937,228
Total Current Assets  (as reported)10,555,119
Total Current Assets  (calculated)9,897,216
+/- 657,903
Long-term Assets
Goodwill 482,993
Long Term Investments 233,646
Intangible Assets 875,729
Long-term Assets Other 77,480
Long-term Assets  (as reported)4,183,874
Long-term Assets  (calculated)1,669,848
+/- 2,514,026

Liabilities & Shareholders' Equity

Total Current Liabilities5,422,989
Long-term Liabilities350,543
Total Stockholder Equity8,965,475
Total Current Liabilities
Short Long Term Debt 80,975
Accounts payable 2,514,255
Total Current Liabilities  (as reported)5,422,989
Total Current Liabilities  (calculated)2,595,230
+/- 2,827,759
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt160,530
Long-term Liabilities  (as reported)350,543
Long-term Liabilities  (calculated)160,530
+/- 190,013
Total Stockholder Equity
Retained Earnings 6,661,858
Total Stockholder Equity (as reported)8,965,475
Total Stockholder Equity (calculated)6,661,858
+/- 2,303,617
Other
Capital Stock435,935
Common Stock Shares Outstanding 871,870
Net Invested Capital 9,046,450
Net Working Capital 5,132,130



Balance Sheet

Currency in THB. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312011-12-31
> Total Assets 
3,227,649
4,135,256
4,491,874
4,883,636
5,147,679
6,535,853
6,874,311
6,547,117
6,524,934
6,722,439
6,736,356
7,009,635
7,255,245
7,612,547
7,338,548
7,328,173
7,471,991
7,940,973
7,815,990
8,222,537
8,326,657
8,719,842
8,476,532
8,768,418
8,602,250
9,632,593
9,972,396
10,092,140
10,191,281
10,532,705
11,189,919
11,325,857
11,693,640
11,589,714
11,430,970
11,733,793
12,548,005
13,271,700
13,639,790
14,470,549
14,074,084
14,646,435
14,701,028
14,697,428
14,738,993
14,738,99314,697,42814,701,02814,646,43514,074,08414,470,54913,639,79013,271,70012,548,00511,733,79311,430,97011,589,71411,693,64011,325,85711,189,91910,532,70510,191,28110,092,1409,972,3969,632,5938,602,2508,768,4188,476,5328,719,8428,326,6578,222,5377,815,9907,940,9737,471,9917,328,1737,338,5487,612,5477,255,2457,009,6356,736,3566,722,4396,524,9346,547,1176,874,3116,535,8535,147,6794,883,6364,491,8744,135,2563,227,649
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,688,893
5,601,599
6,048,110
5,821,096
6,470,143
6,187,528
6,352,813
6,268,947
6,468,614
6,900,413
6,956,848
6,974,404
7,245,836
7,230,612
7,318,963
7,603,887
7,619,823
7,380,400
7,720,951
8,568,085
9,300,879
9,620,392
10,340,694
9,893,184
10,589,994
10,645,467
10,558,440
10,555,119
10,555,11910,558,44010,645,46710,589,9949,893,18410,340,6949,620,3929,300,8798,568,0857,720,9517,380,4007,619,8237,603,8877,318,9637,230,6127,245,8366,974,4046,956,8486,900,4136,468,6146,268,9476,352,8136,187,5286,470,1435,821,0966,048,1105,601,5995,688,89300000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
565,856
518,364
692,124
476,525
477,671
712,145
468,966
442,110
559,532
610,485
846,762
1,078,264
1,247,922
998,011
1,038,747
979,423
1,006,451
1,490,461
1,484,882
1,631,935
2,197,692
2,240,723
2,119,941
1,622,876
2,453,465
2,655,096
2,413,732
2,114,248
2,114,2482,413,7322,655,0962,453,4651,622,8762,119,9412,240,7232,197,6921,631,9351,484,8821,490,4611,006,451979,4231,038,747998,0111,247,9221,078,264846,762610,485559,532442,110468,966712,145477,671476,525692,124518,364565,85600000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
675,556
650,938
673,834
477,559
714,328
731,076
708,423
666,964
381,405
574,473
574,473
236,922
207,142
211,091
211,091
211,091
211,091
371,267
333,660
333,660
333,660
335,412
335,412
335,412
335,412
336,957
336,956
336,957
336,957336,956336,957335,412335,412335,412335,412333,660333,660333,660371,267211,091211,091211,091211,091207,142236,922574,473574,473381,405666,964708,423731,076714,328477,559673,834650,938675,55600000000000000000
       Net Receivables 
1,425,917
1,208,902
1,305,728
1,681,743
1,747,616
1,788,962
1,892,355
1,858,257
2,110,260
2,201,598
2,331,539
2,532,195
2,396,768
2,306,436
2,317,275
2,135,370
2,092,116
2,287,349
2,149,426
2,292,921
2,420,078
2,615,878
2,238,139
2,598,023
2,485,083
2,638,190
2,436,470
2,345,270
2,419,472
2,616,400
2,938,159
2,748,106
2,703,804
2,581,435
2,187,762
2,534,839
2,962,725
2,721,433
3,186,344
3,882,582
3,780,938
3,107,220
3,047,470
3,304,288
3,508,783
3,508,7833,304,2883,047,4703,107,2203,780,9383,882,5823,186,3442,721,4332,962,7252,534,8392,187,7622,581,4352,703,8042,748,1062,938,1592,616,4002,419,4722,345,2702,436,4702,638,1902,485,0832,598,0232,238,1392,615,8782,420,0782,292,9212,149,4262,287,3492,092,1162,135,3702,317,2752,306,4362,396,7682,532,1952,331,5392,201,5982,110,2601,858,2571,892,3551,788,9621,747,6161,681,7431,305,7281,208,9021,425,917
       Other Current Assets 
168,683
160,515
75,489
73,747
68,751
189,605
105,605
115,422
89,783
185,168
138,587
120,444
154,491
305,889
161,701
177,252
154,252
254,530
177,809
216,184
175,107
442,574
234,775
200,457
197,524
254,894
14,390
16,783
19,730
255,295
290,123
177,230
165,152
287,462
286,278
275,046
215,372
162,799
130,315
138,445
170,221
0
0
0
0
0000170,221138,445130,315162,799215,372275,046286,278287,462165,152177,230290,123255,29519,73016,78314,390254,894197,524200,457234,775442,574175,107216,184177,809254,530154,252177,252161,701305,889154,491120,444138,587185,16889,783115,422105,605189,60568,75173,74775,489160,515168,683
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,071,983
3,135,292
3,216,877
3,286,829
3,959,307
4,006,894
4,089,753
3,969,891
4,050,570
4,012,842
3,979,920
3,970,821
4,019,398
4,129,855
4,180,900
4,056,441
4,055,561
4,138,988
4,183,874
4,183,8744,138,9884,055,5614,056,4414,180,9004,129,8554,019,3983,970,8213,979,9204,012,8424,050,5703,969,8914,089,7534,006,8943,959,3073,286,8293,216,8773,135,2923,071,98300000000000000000000000000
       Property Plant Equipment 
368,464
731,847
810,732
853,159
921,275
969,508
1,002,486
1,012,916
987,506
980,141
978,247
991,238
1,013,573
1,031,495
1,019,629
1,192,593
1,169,257
1,164,284
1,142,178
1,117,349
1,193,308
1,183,037
1,233,595
1,274,290
1,260,438
1,425,989
1,544,455
1,635,074
1,693,559
1,770,592
2,222,409
2,194,696
2,307,840
2,213,797
2,236,784
2,176,368
2,081,560
2,102,739
2,174,003
2,194,061
2,171,903
0
0
0
0
00002,171,9032,194,0612,174,0032,102,7392,081,5602,176,3682,236,7842,213,7972,307,8402,194,6962,222,4091,770,5921,693,5591,635,0741,544,4551,425,9891,260,4381,274,2901,233,5951,183,0371,193,3081,117,3491,142,1781,164,2841,169,2571,192,5931,019,6291,031,4951,013,573991,238978,247980,141987,5061,012,9161,002,486969,508921,275853,159810,732731,847368,464
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
153,581
149,879
215,654
215,221
219,472
220,498
223,610
213,130
212,585
212,443
202,332
199,032
199,421
427,829
435,815
442,296
437,318
443,866
453,717
481,095
476,253
480,300
488,673
505,473
465,883
470,095
478,602
482,993
482,993478,602470,095465,883505,473488,673480,300476,253481,095453,717443,866437,318442,296435,815427,829199,421199,032202,332212,443212,585213,130223,610220,498219,472215,221215,654149,879153,58100000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,918
4,844
4,424
206,795
4,229
3,657
76,566
75,390
461,871
258,363
248,582
245,226
240,568
258,008
240,521
205,213
194,469
202,617
206,956
218,530
214,789
213,941
226,777
243,661
222,875
220,616
228,566
233,646
233,646228,566220,616222,875243,661226,777213,941214,789218,530206,956202,617194,469205,213240,521258,008240,568245,226248,582258,363461,87175,39076,5663,6574,229206,7954,4244,8444,91800000000000000000
       Intangible Assets 
5,679
8,926
15,652
20,816
209,504
213,016
217,469
221,322
223,653
230,211
232,417
234,704
234,627
232,700
231,414
239,059
239,262
736,055
720,621
729,649
724,488
733,843
735,622
527,007
512,310
806,132
805,378
794,025
791,346
792,128
864,888
861,304
878,093
874,999
883,104
863,304
885,722
876,886
868,475
874,821
882,360
863,309
862,220
860,893
875,729
875,729860,893862,220863,309882,360874,821868,475876,886885,722863,304883,104874,999878,093861,304864,888792,128791,346794,025805,378806,132512,310527,007735,622733,843724,488729,649720,621736,055239,262239,059231,414232,700234,627234,704232,417230,211223,653221,322217,469213,016209,50420,81615,6528,9265,679
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
25,064
23,701
39,509
25,607
15,769
84,904
29,162
40,048
53,533
72,577
69,178
53,513
33,489
40,996
51,197
68,576
97,299
64,284
77,480
77,48064,28497,29968,57651,19740,99633,48953,51369,17872,57753,53340,04829,16284,90415,76925,60739,50923,70125,06400000000000000000000000000
> Total Liabilities 
1,971,379
2,509,015
2,724,380
3,144,588
3,293,727
2,843,280
3,120,408
2,818,268
2,799,293
2,744,177
2,699,283
2,992,226
3,203,284
3,277,879
2,876,442
2,870,863
3,075,611
3,261,163
2,987,757
3,313,800
3,447,798
3,475,446
3,020,429
3,323,471
3,307,660
3,908,251
3,951,451
4,272,286
4,395,715
4,357,609
4,932,811
4,819,135
5,037,854
4,610,790
4,109,739
4,395,322
5,053,997
5,246,579
5,019,986
5,974,087
5,544,491
5,869,706
5,498,830
5,601,995
5,773,532
5,773,5325,601,9955,498,8305,869,7065,544,4915,974,0875,019,9865,246,5795,053,9974,395,3224,109,7394,610,7905,037,8544,819,1354,932,8114,357,6094,395,7154,272,2863,951,4513,908,2513,307,6603,323,4713,020,4293,475,4463,447,7983,313,8002,987,7573,261,1633,075,6112,870,8632,876,4423,277,8793,203,2842,992,2262,699,2832,744,1772,799,2932,818,2683,120,4082,843,2803,293,7273,144,5882,724,3802,509,0151,971,379
   > Total Current Liabilities 
1,899,461
2,091,435
2,324,947
2,693,182
2,820,360
2,547,407
2,840,884
2,554,205
2,552,224
2,511,426
2,484,835
2,788,011
2,987,143
3,095,241
2,721,683
2,735,763
2,966,860
3,152,888
2,879,212
3,205,633
3,338,753
3,366,226
2,906,146
3,202,914
3,178,282
3,774,942
3,816,270
4,097,134
4,213,590
4,158,166
4,584,518
4,455,549
4,667,099
4,261,663
3,706,119
3,992,325
4,659,291
4,853,355
4,624,525
5,590,429
5,157,354
5,538,040
5,170,875
5,251,583
5,422,989
5,422,9895,251,5835,170,8755,538,0405,157,3545,590,4294,624,5254,853,3554,659,2913,992,3253,706,1194,261,6634,667,0994,455,5494,584,5184,158,1664,213,5904,097,1343,816,2703,774,9423,178,2823,202,9142,906,1463,366,2263,338,7533,205,6332,879,2123,152,8882,966,8602,735,7632,721,6833,095,2412,987,1432,788,0112,484,8352,511,4262,552,2242,554,2052,840,8842,547,4072,820,3602,693,1822,324,9472,091,4351,899,461
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
669,708
445,985
735,712
674,993
512,169
311,530
618,166
0
0
946,229
1,226,396
1,165,943
888,306
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000888,3061,165,9431,226,396946,22900618,166311,530512,169674,993735,712445,985669,70800000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
669,708
445,985
735,712
674,993
512,169
311,530
618,166
0
0
946,229
1,226,396
1,165,943
888,306
795,949
1,081,193
796,069
499,491
259,246
203,238
156,189
168,176
113,554
187,522
257,789
229,180
224,244
274,991
80,975
80,975274,991224,244229,180257,789187,522113,554168,176156,189203,238259,246499,491796,0691,081,193795,949888,3061,165,9431,226,396946,22900618,166311,530512,169674,993735,712445,985669,70800000000000000000
       Accounts payable 
787,145
768,912
883,141
896,605
1,076,285
1,144,738
1,452,560
1,255,448
1,204,377
1,403,926
1,410,209
1,354,696
1,513,359
1,604,214
1,313,020
1,346,849
1,519,833
1,518,603
1,434,242
1,441,047
1,559,850
1,598,159
1,513,623
1,575,404
1,564,114
1,690,770
1,713,519
1,703,818
1,816,502
2,019,591
1,973,590
1,943,201
2,448,183
2,047,757
1,794,744
2,235,361
2,665,863
2,526,618
2,269,949
2,744,970
2,731,246
2,793,380
2,442,944
2,669,993
2,514,255
2,514,2552,669,9932,442,9442,793,3802,731,2462,744,9702,269,9492,526,6182,665,8632,235,3611,794,7442,047,7572,448,1831,943,2011,973,5902,019,5911,816,5021,703,8181,713,5191,690,7701,564,1141,575,4041,513,6231,598,1591,559,8501,441,0471,434,2421,518,6031,519,8331,346,8491,313,0201,604,2141,513,3591,354,6961,410,2091,403,9261,204,3771,255,4481,452,5601,144,7381,076,285896,605883,141768,912787,145
       Other Current Liabilities 
379,321
471,055
498,736
587,580
522,397
617,978
553,343
478,000
531,236
677,722
634,734
837,536
846,755
856,793
980,993
755,237
828,827
971,192
1,003,032
1,030,496
1,103,910
1,255,898
1,080,993
550,933
376,277
244,032
637,145
591,455
646,232
334,447
1,183,601
872,432
747,858
849,307
916,068
865,612
909,722
818,874
1,442,486
1,783,923
1,185,689
0
0
0
0
00001,185,6891,783,9231,442,486818,874909,722865,612916,068849,307747,858872,4321,183,601334,447646,232591,455637,145244,032376,277550,9331,080,9931,255,8981,103,9101,030,4961,003,032971,192828,827755,237980,993856,793846,755837,536634,734677,722531,236478,000553,343617,978522,397587,580498,736471,055379,321
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
135,181
175,152
182,125
199,443
348,293
363,586
370,755
349,127
403,620
402,997
394,706
393,224
395,461
383,658
387,137
331,666
327,955
350,412
350,543
350,543350,412327,955331,666387,137383,658395,461393,224394,706402,997403,620349,127370,755363,586348,293199,443182,125175,152135,18100000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-669,708
-445,985
-735,712
-674,993
-512,169
-311,530
-618,166
0
0
-943,083
-1,223,639
-1,163,521
-886,136
170,959
172,385
167,586
147,976
210,091
209,853
194,457
188,153
184,134
191,643
182,342
191,691
176,976
172,824
160,530
160,530172,824176,976191,691182,342191,643184,134188,153194,457209,853210,091147,976167,586172,385170,959-886,136-1,163,521-1,223,639-943,08300-618,166-311,530-512,169-674,993-735,712-445,985-669,70800000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
112
0
0
332
72
0
0
0
0
0
0
0
0
0
0
00000000007233200112000000000000000000000000000000
> Total Stockholder Equity
1,233,623
1,602,859
1,746,596
1,718,548
1,853,928
3,692,561
3,753,926
3,728,901
3,725,658
3,978,280
4,037,106
4,017,427
4,051,961
4,334,690
4,462,024
4,457,267
4,396,374
4,679,804
4,828,204
4,908,718
4,878,825
5,244,361
5,456,064
5,444,903
5,294,516
5,724,254
6,020,800
5,819,748
5,795,471
6,174,998
6,235,502
6,482,492
6,633,448
6,957,637
7,299,783
7,317,098
7,468,950
8,002,820
8,599,557
8,496,324
8,529,498
8,776,657
9,202,080
9,095,325
8,965,475
8,965,4759,095,3259,202,0808,776,6578,529,4988,496,3248,599,5578,002,8207,468,9507,317,0987,299,7836,957,6376,633,4486,482,4926,235,5026,174,9985,795,4715,819,7486,020,8005,724,2545,294,5165,444,9035,456,0645,244,3614,878,8254,908,7184,828,2044,679,8044,396,3744,457,2674,462,0244,334,6904,051,9614,017,4274,037,1063,978,2803,725,6583,728,9013,753,9263,692,5611,853,9281,718,5481,746,5961,602,8591,233,623
   Retained Earnings 
1,262,105
1,672,858
1,878,527
1,524,381
1,658,602
1,261,814
1,317,548
1,290,639
1,315,384
1,566,320
1,672,307
1,621,487
1,635,540
1,912,249
2,026,221
2,036,637
2,005,522
2,300,491
2,492,213
2,575,199
2,561,632
2,947,173
3,204,039
3,145,378
3,131,610
3,540,077
3,711,064
3,583,641
3,595,489
4,041,212
3,988,740
4,292,099
4,320,252
4,751,586
5,085,134
5,118,602
5,276,336
5,766,336
6,379,828
6,213,621
6,203,846
6,581,013
7,034,011
6,823,834
6,661,858
6,661,8586,823,8347,034,0116,581,0136,203,8466,213,6216,379,8285,766,3365,276,3365,118,6025,085,1344,751,5864,320,2524,292,0993,988,7404,041,2123,595,4893,583,6413,711,0643,540,0773,131,6103,145,3783,204,0392,947,1732,561,6322,575,1992,492,2132,300,4912,005,5222,036,6372,026,2211,912,2491,635,5401,621,4871,672,3071,566,3201,315,3841,290,6391,317,5481,261,8141,658,6021,524,3811,878,5271,672,8581,262,105
   Accumulated Other Comprehensive Income 000000000000000000000000000000000000000000000
   Capital Surplus 000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000



Balance Sheet

Currency in THB. All numbers in thousands.




Cash Flow

Currency in THB. All numbers in thousands.




Income Statement

Currency in THB. All numbers in thousands.